Zenas BioPharma (ZBIO) EBIAT (2023 - 2025)
Zenas BioPharma (ZBIO) has 3 years of EBIAT data on record, last reported at -$51.5 million in Q3 2025.
- For Q3 2025, EBIAT fell 33.43% year-over-year to -$51.5 million; the TTM value through Sep 2025 reached -$189.9 million, down 47.24%, while the annual FY2024 figure was -$157.0 million, 323.15% down from the prior year.
- EBIAT reached -$51.5 million in Q3 2025 per ZBIO's latest filing, up from -$52.2 million in the prior quarter.
- Across five years, EBIAT topped out at $35.6 million in Q3 2023 and bottomed at -$52.6 million in Q4 2024.
- Average EBIAT over 3 years is -$31.5 million, with a median of -$38.0 million recorded in 2024.
- Peak YoY movement for EBIAT: crashed 208.29% in 2024, then decreased 20.77% in 2025.
- A 3-year view of EBIAT shows it stood at -$24.6 million in 2023, then plummeted by 113.84% to -$52.6 million in 2024, then rose by 2.09% to -$51.5 million in 2025.
- Per Business Quant database, its latest 3 readings for EBIAT were -$51.5 million in Q3 2025, -$52.2 million in Q2 2025, and -$33.6 million in Q1 2025.